Ocean Biomedical (OCEA) Has a New Rating from Fundamental Research

In a report released on March 16, Siddharth Rajeev from Fundamental Research initiated coverage with a Buy rating on Ocean Biomedical (OCEAResearch Report) and a price target of $16.40. The company’s shares closed last Friday at $7.17.

According to TipRanks, Rajeev is an analyst with an average return of -2.3% and a 33.06% success rate.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocean Biomedical with a $13.20 average price target, which is an 84.10% upside from current levels. In a report released on March 13, EF Hutton also initiated coverage with a Buy rating on the stock with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $26.60 and a one-year low of $3.06. Currently, Ocean Biomedical has an average volume of 2.57M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aesther Healthcare Acquisition Corp is a newly-organized blank check company. It is formed for the purpose effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Read More on OCEA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More